Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation

Introduction Chronic kidney disease (CKD) after liver transplantation (LT) is a major clinical problem that appears to be associated with nongenetic as well as genetic determinants. Calcineurin inhibitor (CNI) use is considered to play a major role in the development of CKD after LT. We studied the influence of single-nucleotide polymorphisms (SNPs) in the genes of the donor and recipient CNI-metabolizing enzyme CYP3A5 and the CNI-transporting ABCB1 on the development of CKD after LT. Materials and methods Tacrolimus (Tac) predose concentrations at different time-points after transplantation and the CYP3A5 6986A>G and ABCB1 3435C>T SNPs were determined in 125 LT recipients and their respective donors to study the influence of Tac predose levels and genetics on the development of CKD. Results After a median follow-up of 5.7±2.9 years, CKD developed in 47 patients (36%). The Tac predose levels were not correlated with the development of CKD. Neither did we find a correlation between the investigated SNPs in either donor or recipient ABCB1 and CYP3A5 genes (or combinations thereof) and the development of CKD. These genetic variations did not relate to Tac predose blood concentrations in our study. Conclusion An individual’s risk of developing CKD after LT is not associated with genetic variation in either recipient or donor CYP3A5 or ABCB1 genotype status.

[1]  D. Hesselink,et al.  The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation , 2014, Clinical Pharmacokinetics.

[2]  G. Russ,et al.  Validation of an LC–MS/MS Method to Measure Tacrolimus in Rat Kidney and Liver Tissue and Its Application to Human Kidney Biopsies , 2013, Therapeutic drug monitoring.

[3]  W. Weimar,et al.  Genetic Polymorphisms in ABCB1 Influence the Pharmacodynamics of Tacrolimus , 2013, Therapeutic drug monitoring.

[4]  W. Chapman,et al.  Renal Function at Two Years in Liver Transplant Patients Receiving Everolimus: Results of a Randomized, Multicenter Study , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  A. Israni,et al.  Lower Calcineurin Inhibitor Doses in Older Compared to Younger Kidney Transplant Recipients Yield Similar Troughs , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  M. Hebert,et al.  Measurement and Compartmental Modeling of the Effect of CYP3A5 Gene Variation on Systemic and Intrarenal Tacrolimus Disposition , 2012, Clinical pharmacology and therapeutics.

[7]  M. Simmonds,et al.  Donor ABCB1 variant associates with increased risk for kidney allograft failure. , 2012, Journal of the American Society of Nephrology : JASN.

[8]  W. Weimar,et al.  ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[9]  G. Gervasini,et al.  Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation , 2012, Transplant international : official journal of the European Society for Organ Transplantation.

[10]  C. Elie,et al.  Specificity of Histological Markers of Long‐Term CNI Nephrotoxicity in Kidney‐Transplant Recipients Under Low‐Dose Cyclosporine Therapy , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  A. Matas.  Calcineurin Inhibitors: Short‐Term Friend, Long‐Term Foe? , 2011, Clinical pharmacology and therapeutics.

[12]  A. Matas.  Chronic Progressive Calcineurin Nephrotoxicity: An Overstated Concept , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  K. Verbeke,et al.  Tacrolimus Dose Requirements and CYP3A5 Genotype and the Development of Calcineurin Inhibitor-Associated Nephrotoxicity in Renal Allograft Recipients , 2010, Therapeutic drug monitoring.

[14]  D. Hesselink,et al.  The Pharmacogenetics of Calcineurin Inhibitor–Related Nephrotoxicity , 2010, Therapeutic drug monitoring.

[15]  P. Marquet,et al.  Donor P‐gp Polymorphisms Strongly Influence Renal Function and Graft Loss in a Cohort of Renal Transplant Recipients on Cyclosporine Therapy in a Long‐Term Follow‐Up , 2010, Clinical pharmacology and therapeutics.

[16]  M. Sarwal,et al.  Balancing efficacy and toxicity of kidney transplant immunosuppression. , 2009, Transplantation proceedings.

[17]  J. McElnay,et al.  Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. , 2009, British journal of clinical pharmacology.

[18]  B. Charpentier,et al.  Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. , 2008, Basic & clinical pharmacology & toxicology.

[19]  G. Tenderich,et al.  No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[20]  S. Uemoto,et al.  Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients , 2008, Pharmacogenetics and genomics.

[21]  R Kreutz,et al.  CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine , 2008, The Pharmacogenomics Journal.

[22]  E. Lerut,et al.  CYP3A5 and CYP3A4 but not MDR1 Single‐nucleotide Polymorphisms Determine Long‐term Tacrolimus Disposition and Drug‐related Nephrotoxicity in Renal Recipients , 2007, Clinical pharmacology and therapeutics.

[23]  E. Vittinghoff,et al.  Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. , 2007, Archives of internal medicine.

[24]  J. Hegarty,et al.  Chronic kidney disease post-liver transplantation. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  D. Hesselink,et al.  The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? , 2005, Pharmacogenomics.

[26]  H. Ackermann,et al.  ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. , 2005, Journal of the American Society of Nephrology : JASN.

[27]  P. Houillier,et al.  Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. , 2005, Journal of the American Society of Nephrology : JASN.

[28]  S. Masuda,et al.  CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. , 2004, Pharmacogenetics.

[29]  E. Schuetz,et al.  Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. , 2003, Pharmacogenetics.

[30]  P. Beaune,et al.  Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12 , 2003, Transplantation.

[31]  R. Wolfe,et al.  Chronic renal failure after transplantation of a nonrenal organ. , 2003, The New England journal of medicine.

[32]  W. Weimar,et al.  Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus , 2003, Clinical pharmacology and therapeutics.

[33]  P. Syrris,et al.  Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement , 2002, Transplantation.

[34]  W. Weimar,et al.  Evaluation of the new EMIT enzyme immunoassay for the determination of whole-blood tacrolimus concentrations in kidney, heart, and liver transplant recipients. , 2002, Transplantation proceedings.

[35]  R. V. van Schaik,et al.  CYP3A5 variant allele frequencies in Dutch Caucasians. , 2002, Clinical chemistry.

[36]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[37]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Fontana,et al.  Molecular and physical mechanisms of first-pass extraction. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[39]  K. Goa,et al.  Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. , 1997, Drugs.

[40]  P. Maurel,et al.  Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? , 1996, Biochemical and biophysical research communications.

[41]  J. Kolars,et al.  Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[42]  Y. Tanigawara,et al.  Human P-glycoprotein transports cyclosporin A and FK506. , 1993, The Journal of biological chemistry.

[43]  P. Watkins,et al.  Identification of a polymorphically expressed member of the human cytochrome P-450III family. , 1989, Molecular pharmacology.

[44]  T. Kronbach,et al.  Cyclosporine metabolism in human liver: Identification of a cytochrome P‐450III gene family as the major cyclosporine‐metabolizing enzyme explains interactions of cyclosporine with other drugs , 1988, Clinical pharmacology and therapeutics.

[45]  C. Staatz,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation , 2004, Clinical pharmacokinetics.

[46]  Y Zhang,et al.  The Gut as a Barrier to Drug Absorption , 2001, Clinical pharmacokinetics.

[47]  C. Perry,et al.  Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. , 2001, Drugs.